Elizabeth Alcamo, Ph.D.


Liz is an Entrepreneur-in-Residence at Versant and President and CEO at the firm's portfolio company, Seawolf Therapeutics.

Prior to becoming an EIR, Liz was SVP of Corporate Development at Versant’s Inception Therapeutics discovery engine, where she drove new company sourcing and played an integral role in operationalizing two Series A companies. Previously, Liz held various leadership roles driving corporate, science and IP strategy and business development at several emerging gene therapy companies including Avalanche Biotechnologies (now Adverum), 4D Molecular Therapeutics and CODA Biotherapeutics.


Liz has a B.S. from Williams College and completed a Ph.D. in immunology at MIT and postdoctoral research in neurobiology at Stanford University. She is also a registered patent agent and brings over 14 years of experience serving as an IP strategy advisor to biotechnology and pharmaceutical companies, six of those while practicing patent law as a member of the boutique life sciences firm Bozicevic, Field and Francis LLP.